There are 717 resources available
301MO - Genomic HLA as a predictive biomarker for survival among non-small cell lung cancer patient treated with single agent immunotherapy
Presenter: Afaf Abed
Session: Mini oral session on Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
302MO - Development of a flow cytometry-based whole-blood prognostic immune signature in metastatic cancer patients treated with immune checkpoint inhibitors
Presenter: Jian-Guo Zhou
Session: Mini oral session on Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
303MO - Single-cell analysis reveals the interaction between M2 macrophages and NK cells underlying immune types associated with cancer immunotherapy response
Presenter: Anlin Li
Session: Mini oral session on Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
71MO - OBI-833 was safe and immunogenic, without treatment-related SAEs, in a phase I dose-escalation trial
Presenter: Her-shyong Shiah
Session: Mini oral session on Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
47MO - Efficacy and quality of life (QOL) in premenopausal Asian patients (pts) with hormone receptor–positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) treated in the MONALEESA (ML)-7 study
Presenter: Yen-Shen Lu
Session: Mini oral session on Breast cancer
Resources:
Abstract
Slides
Webcast
49MO - IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
Presenter: Hiroji Iwata
Session: Mini oral session on Breast cancer
Resources:
Abstract
Slides
Webcast
356MO - Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence
Presenter: Masahiro Tsuboi
Session: Mini oral session on Thoracic cancers
Resources:
Abstract
Slides
Webcast
366MO - Osimertinib plus platinum/pemetrexed in newly diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study
Presenter: Sang-We Kim
Session: Mini oral session on Thoracic cancers
Resources:
Abstract
Slides
Webcast
381MO - Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
Presenter: Keunchil Park
Session: Mini oral session on Thoracic cancers
Resources:
Abstract
Slides
Webcast
382MO - The preliminary safety result of a phase II study of osimertinib in combination with platinum + pemetrexed in patients with previously untreated EGFR-mutated advanced NSCLC (NEJ032C/LOGIK1801: OPAL)
Presenter: Ryo Morita
Session: Mini oral session on Thoracic cancers
Resources:
Abstract
Slides
Webcast